Business
IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027Initiated Phase 2/3 registrational trial for darovasertib and crizotinib combination in first-line HLA-A2 negative metastatic UM, and also initiated a separate Phase 2 clinical trial to evaluate single-agent darovasertib as neoadjuvant and adjuvant therapy for primary UMTargeting darovasertib clinical program updates in Q4 2023, including ctDNA data from Phase 2 MUM trial at ESMO 2023, as well as prevalence of HLA-A2 (+)/(-) serotypes and clinical data update for darovasertib as neoadjuvant therapy in primary UMFirst patient dosed in Amgen-sponsored Phase 1/2 clinical trial evaluating IDE397 (MAT2A) and AMG 193 (PRMT5MTA) combination in patients with MTAP-deletion solid tumorsIDE397 Phase 2 monotherapy expansion proceeding for MTAP-deletion high-priority tumors – NSCLC, bladder, gastric and esophageal cancersObserved responses to IDE397 monotherapy in multiple MTAP-deletion high-priority tumor types based on experience across several patients in early phase of dose expansionOngoing dose escalation for Phase 1 clinical trial evaluating IDE161 in patients with HRD solid tumors, with strategic focus in ER+, Her2- breast cancerSubmitted IND and anticipating FDA clearance in Q3 2023 for GSK101 (IDE705) Pol Theta Helicase inhibitor in a GSK-sponsored clinical trial, with potential $7 million milestoneTargeting Werner Helicase development candidate with GSK in H2 2023, with potential $3 million milestone from GSK in connection with IND-enabling studiesSOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2023.\n\n \n \n \n \n \n \n\n \n\"We are executing on our clinical strategy to deliver precision medicine therapies to patients and build value for our shareholders. Our broad clinical pipeline includes three potential first-in-class clinical candidates for which we own or control all worldwide commercial rights – darovasertib (PKC), IDE397 (MAT2A) and IDE161 (PARG). We have a fourth potential first-in-class clinical candidate, GSK101 (Pol The...